Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amikacin liposome inhalation suspension
- Development stage
- Approved
- Lead developer
- Insmed
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ARIKAYCE (amikacin liposome inhalation suspension) is an aminoglycoside antibacterial medication delivered via inhalation. It is the first and only FDA-approved treatment for Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. The medication works by preventing bacteria from making certain proteins, which prevents them from surviving and spreading throughout the body. ARIKAYCE is administered once daily using the Lamira Nebulizer System.
- Brand names
- ARIKAYCE
- Other names
- ARIKACE
02
Targets
Bacterial Ribosome
Beyond the preview
Go deeper on amikacin liposome inhalation suspension.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amikacin liposome inhalation suspension.